BACKGROUND: A recent clinical trial concluded that radiation therapy (RT) does not lower the risk of mastectomy and, thus, may be omitted in older women with stage I, estrogen receptor (ER)-positive breast cancer who undergo conservative surgery (CS). However, it is not known whether this finding applies to patients outside of clinical trials. Accordingly, we used the Surveillance, Epidemiology, and End Results-Medicare observational cohort to determine the effect of RT on the risk of mastectomy among older women with stage I, ER-positive breast cancer. METHODS: The authors identified 7403 women ages 70 to 79 years who underwent CS between 1992 and 2002. Claims were used to determine RT status and to identify women who underwent mastectomy subsequent to initial treatment. The Kaplan-Meier method was used to estimate the risk of subsequent mastectomy, and Cox regression analysis was used to determine the effect of RT adjusted for clinical-pathologic covariates. RESULTS: At a median follow-up of 7.3 years, the risk of subsequent mastectomy within 10 years of diagnosis was 3.2% for patients who received RT versus 6.3% for patients who did not receive RT (P < .001). In adjusted analyses, RT was associated with a lower risk of mastectomy (hazard ratio, 0.33; 95% confidence interval, 0.22-0.48; P < .001). RT provided no benefit for patients ages 75 to 79 years without high-grade tumors who had a pathologic lymph node assessment (P = .80); however, for all other subgroups, RT was associated with an absolute reduction in risk of mastectomy that ranged from 4.3% to 9.8% at 10 years. CONCLUSIONS: Outside of a clinical trial, the receipt of RT after CS was associated with a greater likelihood of ultimate breast preservation for most older women with early breast cancer.
BACKGROUND: A recent clinical trial concluded that radiation therapy (RT) does not lower the risk of mastectomy and, thus, may be omitted in older women with stage I, estrogen receptor (ER)-positive breast cancer who undergo conservative surgery (CS). However, it is not known whether this finding applies to patients outside of clinical trials. Accordingly, we used the Surveillance, Epidemiology, and End Results-Medicare observational cohort to determine the effect of RT on the risk of mastectomy among older women with stage I, ER-positive breast cancer. METHODS: The authors identified 7403 women ages 70 to 79 years who underwent CS between 1992 and 2002. Claims were used to determine RT status and to identify women who underwent mastectomy subsequent to initial treatment. The Kaplan-Meier method was used to estimate the risk of subsequent mastectomy, and Cox regression analysis was used to determine the effect of RT adjusted for clinical-pathologic covariates. RESULTS: At a median follow-up of 7.3 years, the risk of subsequent mastectomy within 10 years of diagnosis was 3.2% for patients who received RT versus 6.3% for patients who did not receive RT (P < .001). In adjusted analyses, RT was associated with a lower risk of mastectomy (hazard ratio, 0.33; 95% confidence interval, 0.22-0.48; P < .001). RT provided no benefit for patients ages 75 to 79 years without high-grade tumors who had a pathologic lymph node assessment (P = .80); however, for all other subgroups, RT was associated with an absolute reduction in risk of mastectomy that ranged from 4.3% to 9.8% at 10 years. CONCLUSIONS: Outside of a clinical trial, the receipt of RT after CS was associated with a greater likelihood of ultimate breast preservation for most older women with early breast cancer.
Authors: A P Forrest; H J Stewart; D Everington; R J Prescott; C S McArdle; A N Harnett; D C Smith; W D George Journal: Lancet Date: 1996-09-14 Impact factor: 79.321
Authors: D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud Journal: Lancet Date: 1996-12-07 Impact factor: 79.321
Authors: Aliza K Fink; Jerry Gurwitz; William Rakowski; Edward Guadagnoli; Rebecca A Silliman Journal: J Clin Oncol Date: 2004-08-15 Impact factor: 44.544
Authors: Kevin S Hughes; Lauren A Schnaper; Donald Berry; Constance Cirrincione; Beryl McCormick; Brenda Shank; Judith Wheeler; Lorraine A Champion; Thomas J Smith; Barbara L Smith; Charles Shapiro; Hyman B Muss; Eric Winer; Clifford Hudis; William Wood; David Sugarbaker; I Craig Henderson; Larry Norton Journal: N Engl J Med Date: 2004-09-02 Impact factor: 91.245
Authors: Anthony W Fyles; David R McCready; Lee A Manchul; Maureen E Trudeau; Patricia Merante; Melania Pintilie; Lorna M Weir; Ivo A Olivotto Journal: N Engl J Med Date: 2004-09-02 Impact factor: 91.245
Authors: Julia White; Monica Morrow; Jennifer Moughan; Jean Owen; Thomas Pajak; Susan DesHarnais; David P Winchester; J Frank Wilson Journal: Cancer Date: 2003-02-15 Impact factor: 6.860
Authors: Jacob N Hunnicutt; Christine M Ulbricht; Stavroula A Chrysanthopoulou; Kate L Lapane Journal: Pharmacoepidemiol Drug Saf Date: 2016-09-05 Impact factor: 2.890
Authors: Grace L Smith; Jing Jiang; Thomas A Buchholz; Ying Xu; Karen E Hoffman; Sharon H Giordano; Kelly K Hunt; Benjamin D Smith Journal: Int J Radiat Oncol Biol Phys Date: 2013-11-21 Impact factor: 7.038
Authors: Askal Ayalew Ali; Hong Xiao; Rima Tawk; Ellen Campbell; Anastasia Semykina; Alberto J Montero; Vakaramoko Diaby Journal: Curr Med Res Opin Date: 2016-12-08 Impact factor: 2.705